BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 12, 2022
View Archived Issues
CD22 aberrant splicing confers resistance to therapy in B-ALL
Read More
Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis
Read More
Discovery of novel hybrid compounds as antitubercular agents
Read More
TuA-derived hPep elicits long-term anticancer immunity in mice
Read More
Leo Pharma discloses IL-17 modulators
Read More
Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics
Read More
Anaxis Pharma patents MLKL inhibitors
Read More
Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors
Read More
Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors
Read More
Wigen Biomedicine Technology presents new CDK inhibitors
Read More
CD6-ALCAM pathway is a therapeutic target in SLE
Read More
Methamphetamine harnessed for good in BBB transport
Read More
REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2
Read More
PostEra and Pfizer expand strategic collaboration
Read More
VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo
Read More
Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer
Read More
ABL and Sanofi enter collaboration and license agreement for ABL-301
Read More
G3PP is a therapeutic target for age-related metabolic diseases
Read More
Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI
Read More
A simple method for the synthesis of isoxazole derivatives with in vitro antitumor activity
Read More